FDA product code NYI: Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer
NYI is the FDA product code for classifier, prognostic, recurrence risk assessment, rna gene expression, breast cancer. It is a Class II device, regulated under 21 CFR 866.6040 and reviewed by the Pathology panel. FDA has cleared 9 510(k) submissions under NYI, 1 in the last five years, from 5 different applicants. The average 510(k) review took 268 days (median 246). 1 De Novo request was granted under it. FDA has posted 1 recall for NYI devices.
Definition
A device which uses a gene expression profile of a breast cancer tumor, from patients stage i or stage ii lymph node negative, with a tumor size of <5.0 cm, to provide a risk assessment for distant recurrence of breast cancer. The result is indicated for use only as a prognostic marker by physicians along with a number of other factors to assess the risk of recurrence of breast cancer.
Classification
| Field | Value |
|---|---|
| Device name | Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer |
| Device class | Class II |
| Regulation | 21 CFR 866.6040 |
| Review panel | PA — Pathology |
| Medical specialty | Immunology |
| Premarket route | 510(k) |
510(k) clearances per year for NYI
| Year | Clearances | Avg. review days |
|---|---|---|
| 2020 | 1 | 120 |
| 2022 | 1 | 526 |
Compare with all 510(k) review times · Search every NYI clearance
Top NYI applicants
| Applicant | Clearances | Latest |
|---|---|---|
| Agendia | 3 | 2015-01-23 |
| Agendia, Inc. | 2 | 2022-09-08 |
| Agendia BV | 2 | 2008-07-21 |
| Nanostring Technologies, Inc. | 1 | 2014-11-07 |
| Nanostring Technologies | 1 | 2013-09-06 |
Most recent NYI clearances
| 510(k) | Applicant | Device | Decision date | Review days |
|---|---|---|---|---|
| K210973 | Agendia, Inc. | MammaPrint FFPE NGS Kit | 2022-09-08 | 526 |
| K201902 | Agendia, Inc. | MammaPrint | 2020-11-05 | 120 |
| K141142 | Agendia | MAMMAPRINT FFPE | 2015-01-23 | 266 |
| K141771 | Nanostring Technologies, Inc. | PROSIGNA BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY | 2014-11-07 | 129 |
| K130010 | Nanostring Technologies | PROSIGNA(TM) BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY | 2013-09-06 | 246 |
Recalls for NYI devices
1 product recalls in 1 recall events; 0 initiated in the last five years and 0 still open. Most recent: 2010-03-03.
Frequently asked questions
What is FDA product code NYI?
NYI is the FDA product code for classifier, prognostic, recurrence risk assessment, rna gene expression, breast cancer. It is a Class II device, regulated under 21 CFR 866.6040 and reviewed by the Pathology panel.
What device class is NYI?
Class II, regulation 21 CFR 866.6040. Typical premarket route: 510(k).
How long does a 510(k) take for product code NYI?
Across 9 cleared submissions the average was 268 days from receipt to decision (median 246).
Which companies have the most NYI clearances?
Agendia (3); Agendia, Inc. (2); Agendia BV (2); Nanostring Technologies, Inc. (1); Nanostring Technologies (1).
Have NYI devices been recalled?
Yes: 1 product recalls across 1 recall events; the most recent began 2010-03-03.
Next steps
- Run an FDA pathway report with predicate devices for product code NYI
- Run a recall and safety report across every NYI manufacturer
- Watch product code NYI for new clearances and recalls
Compiled by Caduvo from public U.S. FDA records. Applicant names are shown as FDA records them. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA. Not regulatory advice. Report an error. Data and corrections policy.
All Pathology product codes · FDA product code lookup · 510(k) database search · 510(k) review times